New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Subscribe To Our Newsletter & Stay Updated
